Flag of the European Union EU Clinical Trials Register Help

Clinical trials for breast cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43801   clinical trials with a EudraCT protocol, of which   7272   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,834 result(s) found for: breast cancer. Displaying page 1 of 92.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2016-002120-83 Sponsor Protocol Number: ICO-N-2016-02 Start Date*: 2016-10-05
    Sponsor Name:INSTITUT DE CANCEROLOGIE DE L'OUEST RENE GAUDUCHEAU
    Full Title: Study evaluation of 2nd hormone line response by -[18F]fluoro-17β-œstradiol (FES) PET/CT in metastatic breast cancer patients
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10007305 Carcinoma breast LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-005147-14 Sponsor Protocol Number: DEDiCa Start Date*: 2016-03-16
    Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE
    Full Title: The effect of low dietary glycemic index, excercise and vitamin D on breast cancer recurrence in women
    Medical condition: female breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006860 Ca breast LLT
    20.0 100000004864 10007305 Carcinoma breast LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000698-57 Sponsor Protocol Number: MDV3100-11 Start Date*: 2013-09-01
    Sponsor Name:Medivation, Inc.
    Full Title: A Phase 2, Single-Arm, Open-Label, Multicenter Study of the Clinical Activity and Safety of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple-Negative Breast Cancer
    Medical condition: Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Ongoing) IT (Completed) IE (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2007-000934-38 Sponsor Protocol Number: CP-BR-1-2007 Start Date*: 2007-10-30
    Sponsor Name:Generex Biotechnology Corporation
    Full Title: Prospective, Randomized, Single-Blinded, Multi-Center Phase II Trial of the HER2/neu Peptide GP2 + GM-CSF Vaccine versus GM-CSF Alone in HLA-A2+ OR the Modified HER2/neu Peptide AE37 + GM-CSF Vacci...
    Medical condition: Disease-free, conventionally treated node-positive and high-risk node-negative breast cancer patients who are at significant risk for recurrence.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005349-20 Sponsor Protocol Number: 2/2013 Start Date*: 2013-01-15
    Sponsor Name:Kuopio University Hospital
    Full Title: Diagnostic accuracy of contrast-enhanced ultrasound-guided axillary core biopsy in preoperative staging of the newly diagnosed invasive breast cancer - a prospective study.
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10006192 Breast cancer NOS LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-007257-31 Sponsor Protocol Number: GIC/468 Start Date*: 2008-11-07
    Sponsor Name:IPOLFG
    Full Title: Open-label, single arm, phase II study for evaluation of complete response rate at surgery after NEOadjuvant treatment with SUnitinib and docetaxel in patients with newly diagnosed large operable o...
    Medical condition: large operable and locally advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-016842-22 Sponsor Protocol Number: MK01 Start Date*: Information not available in EudraCT
    Sponsor Name:photonamic GmbH & Co. KG
    Full Title: Evaluation of the suitability of PD L 506 for intraoperative visualisation of palpable and nonpalpable breast cancer tissue
    Medical condition: Breast cancer; palpable and non-palpable tumours of the female breast.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007740-10 Sponsor Protocol Number: TAM-01 Start Date*: 2008-01-30
    Sponsor Name:AZIENDA OSPEDALIERA OSPEDALI GALLIERA
    Full Title: Randomized placebo-controlled phase III trial of low-dose tamoxifen women whit IntraEphitelial Neoplasia(IEN)
    Medical condition: chemoprevention of breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005114-33 Sponsor Protocol Number: s57283 Start Date*: 2015-03-10
    Sponsor Name:UZ Leuven
    Full Title: Effectiveness of Botulinum Toxin Infiltration for treatment of upper limb dysfunctions after treatment for breast cancer
    Medical condition: The aim of this study is to examine the effect of Botolinum Toxine infiltration in the pectoral muscle, in combination with an individual physical therapy programme, on pain and upper limb dysfunct...
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001900-23 Sponsor Protocol Number: 30_04_2014 Start Date*: 2014-10-01
    Sponsor Name:Jari Halonen
    Full Title: METOPROLOLIN VAIKUTUS ANESTESIAAN, KIPULÄÄKKEEN TARPEESEEN JA KIVUN ILMENEMISEEN RINTASYÖPÄLEIKKAUSPOTILAILLA
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10006192 Breast cancer NOS LLT
    Population Age: Adults Gender: Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005863-32 Sponsor Protocol Number: MAST1 Start Date*: 2008-11-27
    Sponsor Name:Department of Oncology
    Full Title: A Phase II Study of Neo-Adjuvant Statin Therapy in Postmenopausal Primary Breast Cancer - a Window-of Opportunity Study
    Medical condition: Postmenopausal women with primary invasive breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002850-35 Sponsor Protocol Number: GEICAM/2016-03 Start Date*: 2017-11-08
    Sponsor Name:GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)
    Full Title: “LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES”.
    Medical condition: Patients with invasive breast cancer in early stages.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002665-35 Sponsor Protocol Number: 190619 Start Date*: 2019-10-14
    Sponsor Name:Mikkel Holm Vendelbo
    Full Title: 16α-18F-fluor-17β-estradiol PET/CT for detection of estrogen receptor positive liver metastases in breast cancer
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005184-42 Sponsor Protocol Number: CLEE011A2412B Start Date*: 2022-04-15
    Sponsor Name:NOVARTIS PHARMA AG
    Full Title: A post-trial access roll-over study to allow access to ribociclib (LEE011) for patients who are on ribociclib treatment in Novartis-sponsored study
    Medical condition: HR+, HER2- advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) ES (Ongoing) PL (Ongoing) PT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003417-14 Sponsor Protocol Number: GEICAM 2006-10 Start Date*: 2007-09-14
    Sponsor Name:Grupo Español de Investigación en Cáncer de Mama (GEICAM)
    Full Title: Ensayo fase III aleatorizado, multicéntrico, abierto, de grupos paralelos para comparar la eficacia y tolerabilidad de Fulvestrant (Faslodex®) durante tres años en combinación con Anastrozol (Arimi...
    Medical condition: Postmenopausal women with operable breast cancer and positive hormonal receptors who are eligible to be treated with adjuvant hormonotherapy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2009-014823-22 Sponsor Protocol Number: LISER-M Start Date*: 2009-07-28
    Sponsor Name:AZIENDA USL DI FORLI`
    Full Title: Second biopsy of axillary sentinel node in the local recurrence of breast cancer after mastectomy and first negative sentinel node. Studio LiSeR - M
    Medical condition: patients with first local recurrence of breast cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-001526-27 Sponsor Protocol Number: STH14707 Start Date*: 2007-06-19
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: ANZAC: A Randomised Phase II Feasibility Study Investigating The Biological Effects of the Addition of Zoledronic Acid To Neoadjuvant Comnination Chemotherapy On Invasive Breast Cancer
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000276-38 Sponsor Protocol Number: MIBIOTIMI Start Date*: 2021-07-06
    Sponsor Name:Álvaro Ruibal Morell
    Full Title: Tumour heterogeneity studies based on dedicated breast PET using proliferation radiotracers: early detection of the treatment response
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003559-39 Sponsor Protocol Number: ICO-A-2018-10 Start Date*: 2018-12-11
    Sponsor Name:INSTITUT DE CANCEROLOGIE DE L'OUEST
    Full Title: multicentric Study , open, randomized, comparing the topical treatment by patch of capsaïcine with 8 % ( Qutenza) to the oral prégabaline treatment in the early treatment of the neuropathic pains a...
    Medical condition: men and /or women older than 18 years with breast cancer for which a surgical operation was realized.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003220-52 Sponsor Protocol Number: CC-486-BRSTM-001 Start Date*: 2015-03-21
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2, Randomized, Open-Label, Two-arm Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant in Postmenopausal...
    Medical condition: Postmenopausal female subjects with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer, who have progressed on an aromatase inhibi...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006315 Breast tumor malignant LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006204 Breast carcinoma LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070575 Estrogen receptor positive breast cancer LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006283 Breast neoplasm malignant female LLT
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) ES (Completed) DE (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA